drugset / Trial / NCT04119336
Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma
Phase 2
Terminated
2 enrolled
Andrew Yee, MD
Bristol-Myers Squibb · collabTakeda Pharmaceuticals North America, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This research is being done to assess the effectiveness and safety of the combination of nivolumab with ixazomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.
Timeline
- Start
- 2020-02-14
- Primary completion
- 2020-11-12
- Completion
- 2022-03-30
Outcome
Outcome not reported
Stopped (Business): “Study closure initiated by industry funding sponsor for commercial reasons.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ixazomib | Unknown | — | Oral |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Dexamethasone | Small molecule | — | Oral |